Sponsor:
Pfizer
Code:
NCT07881757
Conditions
Apnea
Sleep Disorders
Overweight and/or Obesity
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Berobenatide
Placebo
Brief summary:
Conditions
Apnea
Sleep Disorders
Overweight and/or Obesity
Study ID
NCT07881757
Start date
Oct 19, 2026
Status verified date
Nov, 2026
Completion date
Jul 20, 2028
Anticipated
Primary completion date
Jun 1, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
258 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Berobenatide
placebo comparator: Placebo
Interventions
Berobenatide
Placebo
Primary outcome measure
Central contacts
Locations
Cullman Clinical Trials
Recruiting
Cullman, Alabama, United States, 35055
DM Clinical Research-Bradenton
Recruiting
Bradenton, Florida, United States, 34209
Headlands Research - Twin Cities
Recruiting
Maplewood, Minnesota, United States, 55109
Sponsor
Pfizer
Last update posted
Nov 6, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-07. This information was provided to ClinicalTrials.gov by Pfizer on 2026-11-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.